Liposomal formulations of photosensitizers
Source abstract
Abstract
Photodynamic therapy (PDT) is a clinical ablation modality to treat cancers and other diseases. PDT involves administration of a photosensitizer, followed by irradiation of target tissue with light. As many photosensitizers are small and hydrophobic, solubilization approaches and nanoscale delivery vehicles have been extensively explored. Liposomes and lipid-based formulations have been used for the past 30 years, and in some cases have been developed into well-defined commercial PDT products. This review provides an overview of common liposomal formulation strategies for photosensitizers for PDT and also photothermal therapy. Furthermore, research efforts have examined the impact of co-loading therapeutic cargo along with photosensitizers within liposomes. Additional recent approaches including imaging, overcoming hypoxia, upconversion and activatable liposomal formulations are discussed.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. The present and future role of photodynamic therapy in cancer treatment10.1016/S1470-2045(04)01529-3 ↗
2. photobiology, How does photodynamic therapy work?10.1111/j.1751-1097.1992.tb04222.x ↗
3. photobiology, Acute skin response in albino mice following porphyrin photosensitization under oxic and anoxic conditions10.1111/j.1751-1097.1984.tb04614.x ↗
4. Cell death pathways associated with photodynamic therapy: an update10.1111/php.12857 ↗
5. Nanoparticles as vehicles for delivery of photodynamic therapy agents10.1016/j.tibtech.2008.07.007 ↗
6. Current status of liposomal porphyrinoid photosensitizers10.1016/j.drudis.2013.04.003 ↗
7. Preparation and characterization of liposomes as therapeutic delivery systems: a review10.1016/0031-6865(95)00010-7 ↗
8. Liposomes for photodynamic therapy10.1016/j.addr.2003.07.014 ↗
9. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors10.1016/S0031-6997(24)01426-1 ↗
10. Liposomal drug delivery systems: an update review10.2174/156720107782151269 ↗
11. Comparative in vitro study on the characteristics of different photosensitizers employed in PDT10.1016/j.jphotobiol.2010.06.004 ↗
12. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients
13. Photonanomedicine: a convergence of photodynamic therapy and nanotechnology10.1039/C5NR08691D ↗
14. Liposomal nanostructures for photosensitizer delivery10.1002/lsm.21101 ↗
15. Liposomal delivery of photosensitising agents10.1517/17425247.2.3.477 ↗
16. Preferential delivery of liposome-incorporated porphyrins to neoplastic cells in tumour-bearing rats10.1038/bjc.1983.186 ↗
17. Photodynamic therapy of U87 human glioma in nude rat using liposome‐delivered photofrin10.1002/(SICI)1096-9101(1998)22:2<74::AID-LSM2>3.0.CO;2-T ↗
18. Direct detection of singlet oxygen sensitized by haematoporphyrin and related compounds10.1111/j.1751-1097.1986.tb09501.x ↗
19. Pharmacokinetics, tissue distribution and photodynamic therapy efficacy of liposomal‐delivered hypocrellin A, a potential photosensitizer for tumor therapy
20. Drug delivery systems: entering the mainstream10.1126/science.1095833 ↗
21. Recent advances with liposomes as pharmaceutical carriers10.1038/nrd1632 ↗
22. Long-circulating (sterically stabilized) liposomes for targeted drug delivery10.1016/0165-6147(94)90314-X ↗
23. Analytical methods for the control of liposomal delivery systems10.1016/j.trac.2005.07.006 ↗
24. Liposome: methods of preparation and applications
25. Liposome: classification, preparation, and applications10.1186/1556-276X-8-102 ↗
26. Novel methods for liposome preparation10.1016/j.chemphyslip.2013.10.011 ↗
27. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review10.1016/S0168-3659(99)00248-5 ↗
28. Delivering nanomedicine to solid tumors10.1038/nrclinonc.2010.139 ↗
29. Allen · 1998 · 297
30. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models10.1158/0008-5472.CAN-05-4199 ↗
31. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin10.1016/S0168-3659(03)00240-2 ↗
32. Clinical PD/PDT in North America: an historical review10.1016/S1572-1000(04)00084-5 ↗
33. Oncologic photodynamic therapy photosensitizers: a clinical review10.1016/j.pdpdt.2010.02.001 ↗
34. Photodynamic therapy of cancer: an update
35. Photodynamic therapy (PDT)10.1007/BF02833852 ↗
36. Self-assembled liposomal nanoparticles in photodynamic therapy
37. An update on photodynamic therapy in age-related macular degeneration10.1517/14656566.3.7.931 ↗
38. Current clinical and preclinical photosensitizers for use in photodynamic therapy10.1021/jm040074b ↗
39. Photodynamic therapy: applications in dermatology10.1517/14712598.2.1.45 ↗
40. Photodynamic therapy of cancer
41. Photodynamic therapy10.1093/jnci/90.12.889 ↗
42. Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers10.1038/nnano.2015.17 ↗
43. Magnetic targeting of nanotheranostics enhances Cerenkov radiation-induced photodynamic therapy10.1021/jacs.8b09374 ↗
44. New photosensitizers for photodynamic therapy10.1042/BJ20150942 ↗
45. Redistribution of meta-tetra(hydroxyphenyl)chlorin (m-THPC) from conventional and PEGylated liposomes to biological substrates10.1039/c0pp00303d ↗
46. Temoporfin-loaded liposomes: physicochemical characterization10.1016/j.ejps.2010.04.005 ↗
47. Skin penetration and deposition of carboxyfluorescein and temoporfin from different lipid vesicular systems: in vitro study with finite and infinite dosage application10.1016/j.ijpharm.2011.02.006 ↗
48. Temoporfin-loaded liposomal gels: viscoelastic properties and in vitro skin penetration10.1016/j.ijpharm.2009.02.010 ↗
49. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy
50. Drug release characteristics of lipid based benzoporphyrin derivative
51. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery10.1016/j.ejps.2005.05.012 ↗
52. Interaction of liposomal formulations of meta‐tetra (hydroxyphenyl) chlorin (temoporfin) with serum proteins: protein binding and liposome destruction10.1111/j.1751-1097.2012.01176.x ↗
53. Photodynamic therapy with conventional and PEGylated liposomal formulations of mTHPC (temoporfin): comparison of treatment efficacy and distribution characteristics in vivo10.2147/IJN.S51002 ↗
54. U. Isele, P.v. Hoogevest, H. Leuenberger, H.-G. Capraro, K. Schieweck, Pharmaceutical Development of CGP 55847: a Liposomal Zn-Phthalocyanine Formulation Using a Controlled Organic Solvent Dilution Method, SPIE1994.10.1117/12.168680 ↗
55. Stratum corneum lipids liposomes for the topical delivery of 5-aminolevulinic acid in photodynamic therapy of skin cancer: preparation and in vitro permeation study10.1186/1471-5945-1-5 ↗
56. Study on liposomal encapsulation of new Bodipy sensitizers for photodynamic therapy10.1021/acsmedchemlett.7b00490 ↗
57. Intracellular target for photosensitization in cancer antiangiogenic photodynamic therapy mediated by polycation liposome10.1016/j.jconrel.2004.03.030 ↗
58. Enhanced tumor localization and retention of chlorin e6 in cationic nanolipoplexes potentiate the tumor ablation effects of photodynamic therapy10.1088/0957-4484/22/36/365101 ↗
59. CGP 55398, a liposomal Ge (IV) phthalocyanine bearing two axially ligated cholesterol moieties: a new potential agent for photodynamic therapy of tumours10.1038/bjc.1994.160 ↗
60. Thermosensitive liposome formulated indocyanine green for near-infrared triggered photodynamic therapy: in vivo evaluation for triple-negative breast cancer10.1007/s11095-014-1560-7 ↗
61. Photodynamic therapy of 9L gliosarcoma with liposome‐delivered Photofrin10.1111/j.1751-1097.1997.tb01913.x ↗
62. Tumour localisation kinetics of photofrin and three synthetic porphyrinoids in an amelanotic melanoma of the hamster10.1038/bjc.1993.320 ↗
63. Delivery of lipophilic porphyrin by liposome vehicles: preparation and photodynamic therapy activity against cancer cell lines10.1016/j.pdpdt.2014.07.006 ↗
64. Meso-tetraphenyl porphyrin derivatives: the effect of structural modifications on binding to DMPC liposomes and albumin10.1016/j.jphotochem.2010.09.008 ↗
65. Plasmonic liposomes for synergistic photodynamic and photothermal therapy10.1039/c3tb21452d ↗
66. PEGylation of liposome decreases the susceptibility of liposomal drug in cancer photodynamic therapy10.1248/bpb.27.443 ↗
67. Verteporfin PDT for non-standard indications—a review of current literature10.1007/s00417-010-1307-z ↗
68. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial—VIP Report No. 310.1016/S0161-6420(02)01998-X ↗
69. Preliminary studies on a more effective phototoxic agent than hematoporphyrin
70. Current states and future views in photodynamic therapy10.1016/j.jphotochemrev.2011.06.001 ↗
71. The effects of aggregation, protein binding and cellular incorporation on the photophysical properties of benzoporphyrin derivative monoacid ring A (BPDMA)10.1016/1011-1344(95)07174-Z ↗
72. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model10.1111/j.1751-1097.1993.tb02962.x ↗
73. Foscan® uptake and tissue distribution in relation to photodynamic efficacy10.1038/sj.bjc.6600682 ↗
74. Meta-tetra (hydroxyphenyl) chlorin photodynamic therapy in early-stage squamous cell carcinoma of the head and neck10.1001/archotol.129.7.709 ↗
75. mTHPC‐mediated photodynamic therapy for early oral squamous cell carcinoma10.1002/ijc.20209 ↗
76. Comparative characterization of the efficiency and cellular pharmacokinetics of Foscan®-and Foslip®-based photodynamic treatment in human biliary tract cancer cell lines10.1039/b617659c ↗
77. Meta-tetra (hydroxyphenyl) chlorin-loaded liposomes sterically stabilised with poly (ethylene glycol) of different length and density: characterisation, in vitro cellular uptake and phototoxicity10.1039/c1pp05163f ↗
78. K. Schieweck, H.-G. Capraro, U. Isele, P.v. Hoogevest, M. Ochsner, T. Maurer, E. Batt, CGP 55 847, liposome-delivered zinc(II)-phthalocyanine as a phototherapeutic agent for tumors, Proc. SPIE 2078 (1994) 107–118.10.1117/12.168675 ↗
79. Liposome-mediated delivery of photosensitizers: localization of zinc (II)-phthalocyanine within implanted tumors after intravenous administration10.1111/j.1751-1097.1996.tb05670.x ↗
80. Light scattering of human skin: a comparison between zinc (II)—phthalocyanine and photofrin II®10.1016/1011-1344(95)07209-8 ↗
81. Nanodrug applications in photodynamic therapy10.1016/j.pdpdt.2010.12.001 ↗
82. Porphyrin-loaded nanoparticles for cancer theranostics10.1039/C5NR07849K ↗
83. Liposomal photofrin enhances therapeutic efficacy of photodynamic therapy against the human gastric cancer10.1016/S0378-4274(03)00241-8 ↗
84. Plasma membrane-anchorable photosensitizing nanomicelles for lipid raft-responsive and light-controllable intracellular drug delivery10.1016/j.jconrel.2018.07.027 ↗
85. Light-controlled delivery of monoclonal antibodies for targeted photoinactivation of Ki-6710.1021/acs.molpharmaceut.5b00260 ↗
86. Enhanced photodynamic antitumor effect on gastric cancer by a novel photosensitive stealth liposome10.1016/j.phrs.2003.12.015 ↗
87. In vivo photosensitizing efficiency of a diphenylchlorin sensitizer: interest of a DMPC liposome formulation10.1016/S1043-6618(02)00312-2 ↗
88. Activatable photodynamic destruction of cancer cells by NIR dye/photosensitizer loaded liposomes10.1039/C4CC09689D ↗
89. Current status of phthalocyanines in the photodynamic therapy of cancer10.1002/jpp.324 ↗
90. Low-density lipoprotein-bound aluminum sulfophthalocyanine: targeting tumor cells for photodynamic therapy10.1002/jpp.323 ↗
91. Binding of an amphiphilic phthalocyanine to pre-formed liposomes confers light-triggered cargo release10.1039/C8TB01602J ↗
92. BODIPY dyes in photodynamic therapy10.1039/C2CS35216H ↗
93. Dimeric BODIPY-loaded liposomes for dual hypoxia marker imaging and activatable photodynamic therapy against tumors10.1039/C8TB00665B ↗
94. Absorption and emission spectral shifts of rose bengal associated with DMPC liposomes10.1016/j.dyepig.2008.02.003 ↗
95. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy
96. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy10.1016/j.ijrobp.2004.08.006 ↗
97. Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth10.1016/j.canlet.2003.10.001 ↗
98. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response10.1016/j.juro.2007.07.036 ↗
99. Tumor neovasculature-targeted cationic PEGylated liposomes of gambogic acid for the treatment of triple-negative breast cancer10.3109/10717544.2015.1124472 ↗
100. Vessel-targeted chemophototherapy with cationic porphyrin-phospholipid liposomes10.1158/1535-7163.MCT-17-0276 ↗